Transfusion Medicine
Conference Coverage
VALOR: Baby step forward or misstep in AML?
Key clinical point: Vosaroxin plus cytarabine failed to significantly improve overall survival in relapsed or refractory AML, but may offer older...
Conference Coverage
Ofatumumab maintenance halves risk of progression in relapsed CLL
Key clinical point: Maintenance ofatumumab cuts the risk of progression in half among patients with relapsed CLL. Major finding: Progression-free...
Conference Coverage
Brentuximab changes landscape for post-transplant Hodgkin’s lymphoma patients
Key clinical point: Brentuximab vedotin given immediately post-transplant significantly improves progression-free survival in patients with...
Conference Coverage
PD-1 checkpoint inhibitors show mettle against relapsed Hodgkin’s lymphoma
Key clinical point: PD-1 checkpoint inhibition appears to be an effective strategy against treatment-refractory Hodgkin’s lymphoma. Major finding...
News
Vitiligo, alopecia more likely in GVHD when donor is female and recipient is male
Key clinical point: Female-to-male stem cell donation ups the risk for vitiligo in GVHD. Major finding: 14 of the 15 patients who developed...
Conference Coverage
Imatinib appears safe, effective for the long haul
Key clinical finding: Imatinib is safe and effective for treating patients with chronic myeloid leukemia over the course of a decade. Major...
Conference Coverage
Swapping bortezomib for vincristine improves PFS in mantle cell lymphoma
Key clinical point: Substituting bortezomib for vincristine may bring clinical benefit to patients with newly diagnosed mantle cell lymphoma who...
News
Monosomal karyotype, high prognostic risk score predicted transplantation failure
Major finding: Patients with a monosomal karyotype had a 49% relapse rate and a 10% 5-year overall survival rate, and those considered high or...
Conference Coverage
No survival benefit for routine surveillance scans in classical Hodgkin disease
Major finding: The ratio of scans to detected relapses was 18 for the clinical surveillance group and 124 for the routine scan group.